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Abstract
Background: Estradiol, testosterone (T), and sex hormone binding globulin (SHBG) levels are associated with
lipid subfractions in men and women. Our objective was to determine if associations are independent from
adipose tissue area among Asian Indians.
Methods: We used data from 42 women and 57 Asian Indian men who did not use exogenous steroids or lipid-
loweringmedications. Lipoprotein subfractions including low-density lipoprotein cholesterol (LDL), very low-density
lipoprotein cholesterol (VLDL), and intermediate density lipoprotein (IDL) were assessed by ion mobility spec-
trometry. Intra-abdominal adiposity was assessed by computed tomography. Multivariable regression models esti-
mated the association between sex hormones with lipoprotein subfractions before and after adjustment for adiposity.
Results: Among women, lower logSHBG levels were associated with smaller logLDL particle size and higher
logtriglycerides, logVLDL, and logIDL, although these associations were attenuated with adjustment for visceral
adiposity in particular. Among women, lower logSHBG levels was significantly associated with lower logme-
dium LDL and logsmall LDL concentrations even after consideration of visceral and hepatic adiposity and
insulin resistance as represented by the homeostasis model assessment of insulin resistance (HOMA-IR).
Among men, lower logSHBG was also associated with smaller logLDL peak diameter size and higher logtri-
glycerides and logVLDL, even after adjustment for HOMA-IR and adiposity. Relationships between sex steroids
and lipid subfractions were not significant among women. Among men, higher total testosterone was associated
with higher logHDL and logLDL particle size, and lower logtriglycerides and logVLDL, but these associations
were partially attenuated with adjustment for adiposity and HOMA-IR.
Conclusions: Among Asian Indians, SHBG is associated with more favorable lipid subfraction concentrations,
independent of hepatic and visceral fat.
Introduction
Asian Indians represent a quarter of the world’s pop-ulation and are the second fastest growing ethnic group
in the United States, with over 3 million U.S. residents.1 Both
native and migrant Asian Indians have a high prevalence of
diabetes, hypertension, and cardiovascular disease (CVD).2
However, Asian Indians develop these conditions at relatively
low body mass indices compared with other racial/ethnic
groups.2 Thus, the pilot Metabolic Syndrome and Athero-
sclerosis in South Asians Living in America (MASALA)
study was designed to characterize the relationship between
metabolic syndrome and CVD risk in Asian Indians.1
The high risk of the population and unique adiposity
composition also makes it an ideal one in which to study the
relationship between sex steroids and lipids, both of which
have been associated with visceral and hepatic adiposity and
CVD risk.3 Smaller, denser low-density lipoprotein (LDL)
particles are associated with greater risk CVD risk, an effect
that has been found in some studies to be independent of
standard lipid levels, and higher total LDL particle con-
centrations generally reflect denser LDL.4 Similarly, lipo-
protein (a) or Lp(a), an LDL-like particle, increases risk of
CVD independent of conventionally measured lipid levels.5
Finally, recent studies suggest that the high-density lipo-
protein (HDL) inflammatory properties are better predictors
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of the anti-atherogenic properties of HDL than HDL cho-
lesterol levels.6 No studies have examined the relationship
between endogenous sex hormone profiles and measures of
lipoprotein heterogeneity in Asian Indians7 or whether such
associations persist after visceral and hepatic adiposity are
considered. However, in examinations of conventional lipid
profiles, greater androgenicity (as represented by higher
testosterone [T], lower estradiol [E2], and lower sex hor-
mone binding globulin [SHBG]) has been associated with
more atherogenic profiles in women and less atherogenic
profiles in men, and such associations are partially mediated
and/or attenuated after adjustment for visceral and hepatic
adiposity.8
Therefore, we examined the relationships between en-
dogenous sex hormone levels and lipoprotein subclasses
using data from preliminary studies of the MASALA study,
a cohort of Asian Indians in the United States.9 The aim of
this secondary analysis was to determine whether more
androgenic profiles were associated with more atherogenic
lipoprotein subfraction profiles in women and less athero-
genic lipoprotein profiles in men and whether such associ-
ations persisted after consideration of adipose tissue mass.
Methods
From August 2006 to October 2007, the pilot MASALA
study enrolled 150 community-dwelling individuals (75
men and 75 women) living in the San Francisco Bay area
who self-identified as Asian Indian.9 Participants were aged
45–84 years and had no known CVD. Detailed study
methods have been described elsewhere.9 Briefly, this pilot
was population-based, with random sampling of households
in the San Francisco Bay Area with Asian Indian surnames
from the California Health Interview Survey. Individuals
were eligible for the study if they were free from physician-
diagnosed CVD (myocardial infarction, stroke, transient
ischemic attack, congestive heart failure, angina, coronary
artery bypass graft surgery, percutaneous cardiovascular
interventions). Persons were excluded if they could not
speak or understand Hindi or English. For the purposes of
this study, individuals from other South Asian countries
were excluded. Sixty-one percent of eligible participants
who were able to be contacted by telephone were enrolled.
The Institutional Review Board at the University of Cali-
fornia, San Francisco approved the study protocol, and all
study participants provided written informed consent. For this
analysis, we excluded participants who were premenopausal,
as blood draws were not coordinated to the menstrual cycle,
as well as participants who were using lipid-lowering medi-
cation or who were currently using exogenous sex steroid
therapy, leaving a total of 42 women and 57 men.
Sociodemographic characteristics and medical history
were assessed via questionnaire, and use of statins, niacin,
and fibrates were assessed by medication inventory. Partici-
pant weight was determined using a digital scale, height was
measured with a stadiometer, and waist circumference was
taken using a measuring tape at the site of greatest waist
circumference. Visceral and subcutaneous adiposity and he-
patic liver-to-spleen attenuation ratio (values <1 represented
higher amounts of hepatic fat) were measured using com-
puted tomography (CT) (Philips Medical Systems). Visceral
and subcutaneous abdominal fat were measured at the L4–L5
level after participants were positioned supine. Non-enhanced
CT images of liver and spleen density were used to quantify
hepatic fat content. CT scans were digitally recorded for
batched readings by a trained research assistant; intra-
abdominal adipose tissue area was quantified by delineating
the intra-abdominal cavity at the innermost aspect of the
abdominal and oblique muscle walls surrounding the cavity.10
Participants were asked to provide blood samples after a 12-
hour fast. Fasting serum insulin was measured by radioim-
munoassay (Millipore), and the homeostaticmodel assessment
of insulin resistance (HOMA-IR) was calculated as a proxy
measure of insulin resistance using the formula [I0 (mIU/mL) ·
G0 (mmol/L)/22.5].
11 Total cholesterol, triglycerides, and
HDL were measured by enzymatic methods (Quest), and LDL
was calculated.12 Lipoprotein particle subfractions were as-
sessed at the Children’s Hospital Oakland Research Institute
using ion mobility techniques that have been previous de-
scribed.13 Briefly, ion mobility uses an electrospray procedure
to obtain direct lipoprotein particle counts as a function of
particle size; direct comparison of ion mobility techniques
with other methods have demonstrated similar relationships
with degree of atherosclerosis.13 Particle concentrations
(nmol/L) were determined for subfractions defined by the
following size intervals: very low-density lipoprotein (VLDL):
large (42.40–54.70 nm), medium (33.50–42.39 nm), small
(29.60–33.49 nm); intermediate density lipoprotein (IDL):
large (25.00–29.59 nm), small (23.33–24.99 nm); LDL: large
LDL1 (22.46–23.32 nm), medium LDL2a (22.20–22.45 nm)
and LDL2b (21.41–22.19 nm), small LDL3a (20.82–
21.40 nm) and LDL3b (20.49–20.81 nm), and very small
LDL4a (19.90–20.48 nm) and LDL4b (19.00–19.89 nm).
Based upon correlations previously observed between lipo-
protein subfraction measurements,13 LDL fractions 1 and 2a
were classified as large LDL, fraction 2b as medium LDL,
fraction 3a as small LDL, and fractions 3b, 4a, and 4b as very
small LDL. LDL particle concentration was defined as the sum
of LDL subfraction measurements. Intermediate density li-
poprotein (IDL) fraction 1 was classified as large IDL and
IDL2 as small IDL. For the purposes of this analysis, LDL
particle concentrations were calculated as the sum of LDL
particle concentrations, and VLDL fractions consisting of
small, medium, and large particles were combined.13 Inter-
assay variation was less than 15% for all subfractions.
Lp(a) was measured with the BNII nephelometer [N
Latex Lp(a) Reagent; Dade Behring Inc.) utilizing a particle
enhanced immunonepholometric assay at the Laboratory for
Clinical Biochemistry Research at the University of Ver-
mont. The assay range was 10.0–160mg/dL and the mini-
mum detectable level of Lp(a) was 0.20mg/dL. Intraassay
coefficients of variation (CVs) range from 1.8% to 4.1% and
interassay CVs range from 2.0% to 5.3%. 14 The HDL-
inflammatory index was assessed at the University of
California Los Angeles, and methods have been previously
described.15 HDL was isolated from blood samples using
dextran sulfate precipitation. The LDL, necessary in the
cell-free assay for testing the ability of HDL to protect
against LDL oxidation, was aliquotted and cryopreserved in
sucrose. Dichlorofluorescein-diacetate was dissolved in
fresh methanol at 2.0mg/mL, incubated at room temperature,
and protected from light for 30min, which resulted in the
release of dichlorofluorescein that produced an intense fluo-
rescence upon interaction with oxidized lipid. Fluorescence
was determined using a plate reader (Spectra Max, Gemini
XS; Molecular Devices) at an excitation wavelength of
446 KIM ET AL.
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485 nm, an emission wavelength of 530 nm, and a cutoff of
515 nm with the photomultiplier sensitivity set at medium.
For this study, the coefficient of variation for this assay was
9.6%. HDL-inflammatory index was calculated by normal-
izing the assay values obtained for LDL alone as 1.0. If the
addition of a test HDL resulted in a value of 1.0 or greater,
the test HDL was classified as pro-inflammatory or dys-
functional. Conversely, if the addition of the standard normal
LDL together with a test HDL resulted in a value less than
1.0, the test HDL was classified as anti-inflammatory.
E2, T, and SHBG were measured at the Reproductive En-
docrine Research Laboratory at the University of Southern
California. SHBG was measured by a solid-phase, two-site
chemiluminescent assay on the Immulite Analyzer (Siemens
Healthcare Diagnostics). The SHBG assay sensitivity is
1 nmol/L and the interassay CV is <10%. E2 and T were
quantified in serum (0.5mL) by a previously described ra-
dioimmunoassay (RIA) method.10 Prior to RIA, steroids were
extracted with hexane:ethyl acetate (3:2), and then E2 and T
were separated from each other and their metabolites by
Celite column partition chromatography. The assay sensi-
tivities for the E2 and T RIAs are 2 pg/mL and 1.5 ng/dL,
respectively. The interassay coefficients of variation (CVs)
for these assays are 11%, 13%, and 12% at 15, 36, and
101 pg/mL and 8%, 12%, and 12% at 13, 30, and 96 ng/dL,
respectively. Free E2 and T were calculated using a vali-
dated algorithm based on derived equations,16,17 taking the
concentrations of total T, total E2, and SHBG into account
and assuming a fixed albumin concentration of 3.5 g/dL.
We compared baseline characteristics of participants by
sex using chi-squared tests for categorical variables and
Wilcoxon rank-sum tests for continuous variables. We used
a series of sex-stratified multivariable regression models to
examine the association between endogenous sex steroid
hormones and lipoprotein subfractions, before and after
adjustment for visceral adiposity and hepatic density. To
meet model assumptions, lipoprotein subfractions and en-
dogenous sex hormone levels were log-transformed. Finally,
we examined the associations between sex hormones and
LDL and IDL subfractions; models containing both men
and women were constructed and an interaction term for sex
and SHBG included. The prevalence of metabolic syndrome
Table 1. Descriptive Statistics for Respondents, Shown as Median (Interquartile Ratio)
Unless Indicated as N (%)
Women (n = 42) Men (n = 57) P-value
Age (years) 53 (7.6) 56 (14) 0.13
Current smoking, n (%) 0 (0) 0 (0) 0.99
Number of alcoholic beverages per week 0 (1) 2 (7) <0.01
Systolic blood pressure >130mm Hg
or diastolic blood pressure >85mm Hg, n (%)
5 (12) 32 (56) <0.01
Waist circumference >102 cm, n (%) 18 (32)
Waist circumference >88 cm, n (%) 22 (52)
HDL <40mg/dL, n (%) 20 (35)
HDL <50mg/dL, n (%) 15 (35)
Triglycerides >150mg/dL, n (%) 5 (12) 23 (40) <0.01
Fasting glucose >100mg/dL, n (%) 7 (17) 26 (46) <0.01
Presence of metabolic syndrome, n (%) 6 (14) 13 (23) 0.29
BMI (kg/m2) 24.3 (5.4) 25.9 (5.8) 0.21
Waist circumference (cm) 89 (18) 97 (13) <0.01
Visceral fat area (per SD cm2) 98.2 (53.7) 145.0 (66.5) <0.01
Liver-to-spleen attenuation ratio (HU) 1.3 (0.2) 1.2 (0.3) 0.17
HOMA-IR (mg/dL  mIU/L) 2.0 (1.4) 3.1 (3.3) <0.01
Total E2 ( pg/mL) 16.5 (59.5) 41.0 (14.5) <0.01
Total T (ng/dL) 27.1 (13.7) 415.9 (340.2) <0.01
SHBG (nmol/L) 46.2 (29.1) 27.9 (15.5) <0.01
Free E2 ( pg/mL) 0.4 (0.9) 1.2 (0.5) <0.01
Free T (ng/dL) 4.8 (3.3) 128.5 (75.1) <0.01
LDL cholesterol (mg/dL) 109 (40) 113 (43) 0.31
HDL cholesterol (mg/dL) 53 (20) 44 (14) <0.01
Triglycerides (mg/dL) 109 (54) 117 (104) 0.13
VLDL combined (mg/dL) 125.0 (56.1) 23.0 (21.0) 0.01
LDL peak diameter (A˚) 222.7 (5.0) 218.5 (10.0) <0.01
LDL particle concentration (nmol/L) 1789.2 (430.8) 1986.4 (533.1) <0.01
HDL inflammatory index 0.37 (0.36) 0.39 (0.51) 0.66
Lipoprotein a (g/L) 0.18 (0.23) 0.12 (0.17) 0.12
Large IDL (nmol/L) 145.6 (67.2) 164.5 (75.3) 0.09
Small IDL (nmol/L) 227.2 (89.9) 185.0 (58.6) <0.01
Large LDL (nmol/L) 268.8 (110.5) 250.5 (113.3) 0.41
Medium LDL (nmol/L) 234.9 (113.7) 302.1 (137.7) <0.01
Small LDL (nmol/L) 138.8 (72.0) 232.2 (250.2) <0.01
Very small LDL (nmol/L) 172.3 (54.6) 199.8 (179.8) <0.01
BMI, body mass index; E2, estradiol; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance;
HU, Hounsfield units; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; SHBG, sex hormone binding globulin; T,
testosterone; VLDL, very low-density lipoprotein.
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was determined using the modified Adult Treatment Panel
III definition.18 The analysis was completed using SAS
version 9.3, SAS Institute.
Results
Participant characteristics are shown in Table 1. Few par-
ticipants were smokers and most women had less than one
alcoholic beverage per week. Despite the lack of known
CVD, elevated waist circumference, and HDL abnormalities
were common among women and elevations in glucose, hy-
pertension, and elevated triglycerides were common among
men. Fourteen percent of women had metabolic syndrome,
compared with 23% of men. Men had higher levels of vis-
ceral fat but similar levels of hepatic density compared with
women. Despite the fact that the majority of adults were not
obese, the median HOMA-IR for both men and women were
elevated.19 Consistent with the lack of baseline CVD, the
Table 2. Associations Between Sex Hormones and Lipoprotein Fractions
in Women, Beta-coefficient (P-value)
SHBG E2 T
log LDL (mg/dL)
Unadjusted -0.03 (P = 0.09) -0.05 (P = 0.06) 0.01 (P = 0.92)
Model 1* -0.08 (P = 0.20) -0.03 (P = 0.31) 0.03 (P = 0.65)
Model 1, and visceral adiposity (SD3) -0.09 (P = 0.27) -0.03 (P = 0.29) 0.05 (P = 0.52)
Model 1, and hepatic density (HU) -0.09 (P = 0.23) -0.03 (P = 0.32) 0.01 (P = 0.90)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.09 (P = 0.33) -0.03 (P = 0.38) 0.0 (P = 0.97)
log HDL (nmol/L)
Unadjusted 0.15 (0.06) 0.0 (P = 0.81) 0.04 (P = 0.68)
Model 1* 0.13 (P = 0.12) 0.01 (0.78) 0.06 (P = 0.58)
Model 1, and visceral adiposity (SD3) 0.0 (P = 0.93) 0.02 (P = 0.57) -0.01 (P = 0.91)
Model 1, and hepatic density (HU) 0.21 (P5 0.05) 0.04 (P = 0.38) 0.09 (P = 0.45)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.09 (P = 0.45) 0.03 (P = 0.48) 0.02 (P = 0.88)
log Triglycerides (mg/dL)
Unadjusted 20.27 (P5 0.008) 0.0 (P = 0.93) -0.25 (P = 0.054)
Model 1* 20.33 (P5 0.002) 0.03 (P = 0.55) -0.25 (P = 0.08)
Model 1, and visceral adiposity (SD3) -0.16 (P = 0.20) 0.02 (P = 0.74) -0.14 (P = 0.27)
Model 1, and hepatic density (HU) 20.24 (P5 0.05) -0.03 (P = 0.53) -0.20 (P = 0.11)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.17 (P = 0.24) -0.03 (P = 0.62) -0.14 (P = 0.28)
log VLDL (nmol/L)
Unadjusted -0.14 (P = 0.18) -0.07 (P = 0.15) -0.17 (P = 0.21)
Model 1* 20.23 (P5 0.02) -0.02 (P = 0.72) -0.14 (P = 0.27)
Model 1, and visceral adiposity (SD3) -0.20 (P = 0.13) -0.03 (P = 0.56) -0.09 (P = 0.49)
Model 1, and hepatic density (HU) 20.52 (P5 0.0005) -0.06 (P = 0.25) -0.08 (P = 0.47)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.15 (P = 0.33) -0.06 (P = 0.31) -0.09 (P = 0.51)
log LDL peak diameter (A˚)
Unadjusted 0.01 (P5 0.02) 0.0 (P = 0.19) 0.01 (P = 0.33)
Model 1* 0.02 (P5 0.02) 0.0 (P = 0.16) 0.01 (P = 0.37)
Model 1, and visceral adiposity (SD3) 0.01 (P5 0.03) 0.0 (P = 0.22) 0.01 (P = 0.76)
Model 1, and hepatic density (HU) 0.02 (P5 0.01) 0.0 (P = 0.63) 0.01 (P = 0.38)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.02 (P = 0.07) 0.0 (P = 0.70) 0.0 (P = 0.55)
LDL particle concentration (nmol/L)
Unadjusted 20.13 (P5 0.01) -0.02 (P = 0.39) -0.06 (P = 0.36)
Model 1* 20.16 (P5 0.002) -0.02 (P = 0.52) -0.04 (P = 0.51)
Model 1, and visceral adiposity (SD3) -0.11 (P = 0.08) -0.02 (P = 0.51) 0.0 (P = 0.98)
Model 1, and hepatic density (HU) 20.16 (P5 0.01) -0.02 (P = 0.41) -0.03 (P = 0.56)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.11 (P = 0.12) -0.02 (P = 0.54) -0.03 (P = 0.64)
log Lp(a) (g/L)
Unadjusted 0.12 (P = 0.60) -0.11 (P = 0.29) 0.24 (P = 0.43)
Model 1* 0.05 (P = 0.83) -0.07 (P = 0.56) 0.28 (P = 0.37)
Model 1, and visceral adiposity (SD3) 0.04 (P = 0.91) -0.07 (P = 0.57) 0.27 (P = 0.41)
Model 1, and hepatic density (HU) 0.05 (P = 0.88) -0.11 (P = 0.44) 0.18 (P = 0.59)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.0 (P = 0.99) -0.11 (P = 0.45) 0.10 (P = 0.78)
log HDL inflammatory index
Unadjusted -0.13 (P = 0.44) 0.03 (P = 0.70) 0.15 (P = 0.49)
Model 1* -0.15 (P = 0.34) 0.07 (P = 0.39) 0.18 (P = 0.37)
Model 1, and visceral adiposity (SD3) 0.05 (P = 0.88) 0.06 (P = 0.48) 0.30 (P = 0.14)
Model 1, and hepatic density (HU) -0.13 (P = 0.54) 0.08 (P = 0.36) 0.17 (P = 0.44)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.04 (P = 0.87) 0.10 (P = 0.29) 0.31 (P = 0.17)
*Model 1 includes age (years), current smoking, and number of drinks per week.
Figures in bold are significant.
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HDL inflammatory index was not elevated.15 Men had
greater levels of total E2 and total T and lower levels of
SHBG compared with women. Men also had higher LDL
article concentrations and higher concentrations of smaller
lipid subfractions including medium LDL, small LDL, and
very small LDL compared with women.
Table 2 shows the associations between SHBG and lipid
subfractions and standard triglycerides, HDL, and LDL
among women. Lower SHBG levels were associated a more
atherogenic profile, particularly, higher levels of triglycer-
ides, VLDL, smaller LDL peak diameter size, and greater
particle concentrations. These relationships were attenuated
by adjustment for visceral adiposity in particular. Levels of
total E2 and T were not associated with lipid subfractions or
activity before or after adjustment.
Table 3 shows the associations between sex hormones
and lipoprotein subgroups and activity in men. Similar to
women, lower SHBG was associated with a more athero-
genic profile, particularly with higher levels of triglycerides,
VLDL, and smaller peak diameter size. These associations
Table 3. Associations Between Sex Hormones and Lipoprotein Subfractions in Men
SHBG E2 T
log LDL (mg/dL)
Unadjusted -0.05 (P = 0.51) 0.09 (P= 0.51) 0.04 (P = 0.58)
Model 1* 0.05 (P = 0.60) 0.10 (P= 0.45) 0.13 (P = 0.12)
Model 1, and visceral adiposity (SD3) 0.03 (P = 0.33) 0.06 (P= 0.66) 0.15 (P = 0.13)
Model 1, and hepatic density (HU) 0.05 (P = 0.57) 0.10 (P= 0.54) 0.15 (P = 0.11)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.00 (P = 0.97) -0.02 (P= 0.91) 0.11 (P = 0.32)
log HDL (mg/dL)
Unadjusted 0.23 (P5 0.003) 0.29 (P5 0.03) 0.22 (P5 0.006)
Model 1* 0.16 (P = 0.07) 0.25 (P5 0.05) 0.17 (P5 0.03)
Model 1, and visceral adiposity (SD3) 0.13 (P = 0.19) 0.24 (P= 0.08) 0.16 (P = 0.11)
Model 1, and hepatic density (HU) 0.16 (P = 0.09) 0.31 (P5 0.04) 0.18 (P5 0.04)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.11 (P = 0.29) 0.27 (P= 0.10) 0.15 (P = 0.19)
log Triglycerides (mg/dL)
Unadjusted 20.61 (P < 0.0001) 0.02 (P= 0.94) 20.54 (P < 0.001)
Model 1* 20.52 (P5 0.002) 0.14 (P= 0.59) 20.44 (P5 0.006)
Model 1, and visceral adiposity (SD3) 20.41 (P5 0.02) 0.20 (P= 0.47) -0.32 (P = 0.10)
Model 1, and hepatic density (HU) 20.49 (P5 0.003) -0.11 (P= 0.71) 20.39 (P5 0.02)
Model 1, visceral adiposity, hepatic density, HOMA-IR 20.46 (P5 0.02) -0.02 (P= 0.95) -0.37 (P = 0.08)
log VLDL (nmol/L)
Unadjusted 20.60 (P < 0.0001) -0.11 (P= 0.65) 20.49 (P5 0.0007)
Model 1* 20.53 (P5 0.0003) 0.03 (P= 0.90) 20.42 (P5 0.003)
Model 1, and visceral adiposity (SD3) 20.42 (P5 0.009) 0.11 (P= 0.67) -0.27 (P = 0.12)
Model 1, and hepatic density (HU) 20.29 (P5 0.03) -0.16 (P= 0.56) 20.40 (P5 0.009)
Model 1, visceral adiposity, hepatic density, HOMA-IR 20.47 (P5 0.005) -0.08 (P= 0.78) -0.33 (P = 0.09)
log LDL peak diameter (A˚)
Unadjusted 0.02 (P5 0.002) 0.01 (P= 0.39) 0.02 (P5 0.009)
Model 1* 0.02 (P5 0.01) 0.01 (P= 0.63) 0.02 (P5 0.02)
Model 1, and visceral adiposity (SD3) 0.02 (P5 0.04) 0.01 (P= 0.41) 0.02 (P = 0.10)
Model 1, and hepatic density (HU) 0.02 (P5 0.02) 0.02 (P= 0.15) 0.02 (P5 0.04)
Model 1, visceral adiposity, hepatic density, HOMA-IR 0.02 (P5 0.04) 0.02 (P= 0.18) 0.02 (P = 0.08)
log LDL particle concentration (nmol/L)
Unadjusted 20.19 (P5 0.002) 0.06 (P= 0.60) 20.14 (P5 0.04)
Model 1* -0.14 (P = 0.052) 0.09 (P= 0.39) -0.08 (P = 0.21)
Model 1, and visceral adiposity (SD3) -0.08 (P = 0.29) 0.16 (P= 0.16) 0.0 (P = 0.99)
Model 1, and hepatic density (HU) -0.12 (P = 0.11) 0.03 (P= 0.79) -0.06 (P = 0.45)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.11 (P = 0.16) 0.05 (P= 0.69) -0.03 (P = 0.69)
log Lp(a) (g/L)
Unadjusted -0.15 (P = 0.56) -0.27 (P= 0.55) -0.16 (P = 0.55)
Model 1* 20.58 (P5 0.04) -0.46 (P= 0.31) -0.34 (P = 0.21)
Model 1, and visceral adiposity (SD3) -0.61 (P = 0.06) -0.80 (P= 0.09) -0.37 (P = 0.25)
Model 1, and hepatic density (HU) -0.67 (P = 0.06) -0.75 (P= 0.13) -0.33 (P = 0.23)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.44 (P = 0.20) -0.52 (P= 0.33) -0.11 (P = 0.76)
log HDL inflammatory index
Unadjusted -0.40 (P = 0.14) 0.13 (P= 0.80) -0.32 (P = 0.27)
Model 1* -0.19 (P = 0.54) 0.18 (P= 0.72) -0.14 (P = 0.63)
Model 1, and visceral adiposity (SD3) -0.37 (P = 0.32) 0.20 (P= 0.72) -0.42 (P = 0.30)
Model 1, and hepatic density (HU) -0.27 (P = 0.41) 0.52 (P= 0.39) -0.27 (P = 0.41)
Model 1, visceral adiposity, hepatic density, HOMA-IR -0.41 (P = 0.30) 0.62 (P= 0.35) -0.57 (P = 0.21)
*Model 1 includes age (years), current smoking, and number of drinks per week.
Figures in bold are significant.
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remained significant even after adjustment for visceral adi-
posity, hepatic adiposity, and insulin resistance. Among
men, higher levels of E2 were associated with greater con-
centrations of HDL, but this relationship was not significant
after attenuation for visceral adiposity. In contrast to wo-
men, higher levels of total testosterone were associated with
more favorable lipid profiles, particularly, higher levels of
HDL, lower levels of triglycerides and VLDL, and larger
LDL peak diameter size. These relationships were attenu-
ated by visceral adiposity.
Table 4 shows the associations of SHBG with IDL and
LDL particle sizes in men and women. Among women,
higher SHBG levels were associated with lower concentra-
tions of medium LDL and small LDL. These associations
were not observed in men, although the P-value for the
interaction term between sex and SHBG levels was not
significant in any models, and the lack of significance may
have been determined by sample size. In sensitivity analy-
ses, free E2 and free T were not associated with lipid sub-
fractions in women, similar to analyses of total E2 and total
T. In men, free E2 and free T were not associated with lipid
subfractions in men in fully adjusted models, and the as-
sociations between free T and lipid subfractions in men was
attenuated, suggesting that SHBG was a significant con-
tributor to the associations observed between total sex ste-
roids and lipid subfractions (results not shown).
Discussion
Using a population-based sample of Asian Indians in the
United States, we found that higher SHBG levels were as-
sociated with a slightly less atherogenic lipid profile among
both men and women. This association persisted even after
adjustment for CT measures of visceral adiposity and he-
patic density and insulin resistance. Among men and wo-
men, sex steroids E2 and T did not have strong or consistent
associations with lipid subclasses.
Few studies have examined the relationship between en-
dogenous sex hormones and lipid subclasses.7,20–22 Only one
report has examined both men and women.7 Similar to our
findings, the Multi-Ethnic Study of Atherosclerosis (MESA)
also reported that higher SHBG levels were associated with a
less atherogenic profile in both men and women.7 SHBG was
directly associated with greater LDL particle size as well as
Table 4. Associations Between SHBG and Subfractions in Women and Men
Women Men
log Large IDL (nmol/L)
Unadjusted model -0.13 (P= 0.11) -0.19 (P = 0.054)
Model 1 20.20 (P5 0.01) -0.10 (P = 0.39)
Model 1, and visceral adiposity (SD3) 20.21 (P5 0.04) -0.06 (P = 0.64)
Model 1, and hepatic density (HU) 20.21 (P5 0.04) -0.08 (P = 0.51)
Model 1, visceral adiposity, hepatic density, and HOMA-IR -0.22 (P= 0.07) -0.08 (P = 0.57)
log Small IDL (nmol/L)
Unadjusted model 0.15 (P= 0.08) 0.10 (P = 0.18)
Model 1 0.11 (P= 0.20) 0.08 (P = 0.38)
Model 1, and visceral adiposity (SD3) 0.0 (P= 0.98) 0.06 (P = 0.53)
Model 1, and hepatic density (HU) 0.17 (P= 0.12) 0.09 (P = 0.33)
Model 1, visceral adiposity, hepatic density, and HOMA-IR 0.09 (P= 0.47) 0.06 (P = 0.56)
log Large LDL (nmol/L)
Unadjusted model -0.08 (P= 0.30) 0.02 (P = 0.83)
Model 1 -0.12 (P= 0.15) 0.15 (P = 0.23)
Model 1, and visceral adiposity (SD3) -0.05 (P= 0.65) 0.19 (P = 0.16)
Model 1, and hepatic density (HU) -0.17 (P= 0.06) 0.15 (P = 0.23)
Model 1, visceral adiposity, hepatic density, and HOMA-IR -0.05 (P= 0.61) 0.18 (P = 0.22)
log Medium LDL (nmol/L)
Unadjusted model 20.28 (P5 0.003) 20.20 (P5 0.03)
Model 1 20.32 (P < 0.001) -0.07 (P = 0.49)
Model 1, and visceral adiposity (SD3) 20.27 (P5 0.02) -0.06 (P = 0.60)
Model 1, and hepatic density (HU) 20.37 (P5 0.002) -0.07 (P = 0.55)
Model 1, visceral adiposity, hepatic density, and HOMA-IR 20.31 (P5 0.03) -0.10 (P = 0.44)
log Small LDL (nmol/L)
Unadjusted model 20.38 (P5 0.002) 20.43 (P5 0.006)
Model 1 20.42 (P5 0.001) -0.35 (P = 0.057)
Model 1, and visceral adiposity (SD3) 20.35 (P5 0.03) -0.32 (P = 0.13)
Model 1, and hepatic density (HU) 20.41 (P5 0.009) -0.33 (P = 0.08)
Model 1, visceral adiposity, hepatic density, and HOMA-IR 20.41 (P5 0.03) -0.40 (P = 0.07)
log Very small LDL (nmol/L)
Unadjusted model 0.08 (P= 0.12) 20.28 (P5 0.03)
Model 1 -0.16 (P= 0.06) 20.31 (P5 0.05)
Model 1, and visceral adiposity (SD3) -0.10 (P= 0.35) -0.26 (P = 0.15)
Model 1, and hepatic density (HU) -0.15 (P= 0.12) -0.28 (P = 0.10)
Model 1, visceral adiposity, hepatic density, and HOMA-IR -0.15 (P= 0.22) -0.33 (P = 0.07)
Figures in bold are significant.
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inversely correlated with smaller LDL particle size. In con-
trast to our findings, SHBG was also directly related to HDL
concentrations and inversely correlated with VLDL. Also in
contrast to our findings, higher E2 levels were associated with
a more atherogenic profile, consisting of smaller LDL particle
size and higher HDL concentrations.
This difference in results may also be due to our smaller
sample size, as the association between SHBG and HDL
concentrations in the current study was borderline before
adjustment for measures of adiposity. We may also have not
found associations between SHBG and HDL and VLDL and
between E2 and lipoprotein levels due to the adjustment for
adiposity by CT; in our report, the association between
SHBG and VLDL concentrations was attenuated after ad-
justment for visceral adiposity and hepatic density.
The difference in results may also be due to differences in
endogenous sex steroid levels and/or lipid levels in the
MASALA versus MESA populations. Participants in MESA
were white, African American, Hispanic, or Chinese, whereas
participants in MASALA were Asian Indian. Comparisons of
Pakistani, non-Hispanic white European, and African Carib-
bean men living in England have reported lower total T and
SHBG levels in Pakistanis than in other racial/ethnic
groups.23 (Racial/ethnic comparisons of sex steroids in South
Asian women vs. other populations have not been reported.)
Moreover, previous comparisons of racial/ethnic groups have
noted that even after adjustment for visceral, subcutaneous,
and hepatic density, Asian Indians have lower insulin sensi-
tivity using hyperinsulinemic euglycemic clamp studies
compared with other Asian groups.24 In turn, insulin sensi-
tivity is a known modifier of lipid particle size and activity,
with greater insulin resistance contributing to lower HDL
levels.25 Thus, relationships between sex hormones and HDL
may have been attenuated in the current analysis.
In one report examining middle-aged men, SHBG levels
were inversely correlated with apolipoprotein A1, the major
protein component of HDL, and higher T levels were directly
correlated with apolipoprotein B, the major protein compo-
nent of LDL.26 LDL subfractions were not examined, but this
report suggests that the relationships between SHBG and
lipids might extend to other lipoprotein subfractions. Of note,
associations were attenuated with adjustment for waist-to-hip
ratio—an anthropometric proxy for body fat—underlining the
importance of adjusting for this confounder.26 Studies ex-
amining correlations between endogenous sex hormone pro-
files with lipid subfractions among women with and without
polycystic ovarian syndrome have had conflicting results. In
one report, total T was not associated with lipid subfractions,
including LDL subclasses 21; associations between SHBG or
other sex steroids with and lipid fractions were not reported.
Another study noted that SHBG was the strongest correlate of
LDL particle size and number, as well as VLDL number and
size.22 Although total T was not correlated with lipid frac-
tions, lower T after adjustment for SHBG did predict in-
creased LDL particle size. Finally, greater total T levels
correlated with lower HDL in another report, but associations
between SHBG and lipid subfractions were not reported.20
Strengths of this report include the novel assessments of
lipid subfractions and sex hormone profiles in Asian Indians,
a population at high risk for atherogenesis. The cohort,
while small, was also population-based rather than referral
center based. Additional strengths include the CT assess-
ment of intra-abdominal adipose tissue depots, an important
measurement given the strong correlations between sex
hormones and fat in midlife adults. The primary limitation
of the study is its small sample size and conduction of
multiple comparisons, and it is possible that we were un-
derpowered to detect relatively weaker associations between
sex steroids and lipoproteins, particularly in an ethnic group
that may have low sex hormone levels. We note that pre-
menopausal women have higher estradiol as well as testos-
terone levels, and it is possible that this population has a
different pattern of associationswith lipoproteins than reported
here. The MASALA pilot study also did not have measure-
ments of ApoA1 and ApoB or HDL subfractions. However, a
larger MASALA cohort consisting of approximately 900
South Asians (including Asian Indians as well as other South
Asian populations) has been assembled, enabling future ex-
amination of sex steroids, adiposity, and lipid measures. The
value of lipid subfractions and activity versus conventional
CVD risk factor assessment is controversial, and lipid sub-
fractions are not currently recommended for risk stratification
purposes.27–29 Future examinations will determine whether
lipoprotein subfractions have additional discriminatory value
for CVD risk prediction among this population with high
levels of insulin resistance. Future investigations in larger
subsets may help us understand the pathophysiology of ath-
erosclerosis in men and women by examining whether sex
steroids may influence CVD risk via alterations in lipid sub-
fractions apart from ectopic fat deposition.
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